Intellia Therapeutics Inc (NTLA)

Intellia Therapeutics Inc (NTLA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.6B; returns 1 day +0.4%, 1 week -1.8%, 1 year -56.7%.

Intellia Therapeutics Inc. (NTLA) is a clinical-stage biotechnology company focused on developing revolutionary CRISPR-based gene editing therapies for severe genetic diseases. The company's revenue primarily stems from strategic collaborations and licensing agreements, including upfront payments, research funding, and milestone payments. As of January 2026, it does not generate product sales.

Groups NTLA belongs to

• Biotechnology
• Clinical Stage Biotech
• Gene Therapy
• Life Sciences
• Biopharmaceutical
• Healthcare
• Rare Diseases
• Clinical Stage
• Precision Medicine

NTLA financial model: income statement, cash flow and balance sheet